Rat IgG2b Isotype Control [Clone 1-2] — Purified in vivo PLATINUM™ Functional Grade
Antibody DetailsProduct DetailsHost Species Rat Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C Working Concentration This isotype control antibody should be used at the same concentration as the primary antibody. RRIDAB_2831723 Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionSpecificity This Rat IgG2b κ isotype control antibody has been tested against selected species' cells and tissues to assure minimal cross-reactivity. This antibody was also pathogen tested and third-party certified by IDEXX BioReseach to meet the lowest mycoplasma specification and free of any viral pathogens of concern. Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 1-2 is most commonly used as a rat IgG2b isotype control in murine in vivo experiments, rather than as a function-blocking or depleting antibody. Its primary application is to serve as a negative control when testing other rat IgG2b monoclonal antibodies in mice. Essential context and supporting details:
Additional relevant information:
In summary, clone 1-2’s main in vivo application in mice is as a rat IgG2b isotype control, ensuring experimental rigor when using other monoclonal antibodies of the same isotype. When considering antibodies commonly used alongside those targeting 1. Tumour Necrosis Factor (TNF) and 2. Programmed Death-1 (PD-1), several notable examples are mentioned in the literature: Commonly Used Antibodies
Proteins Used in Conjunction with Antibodies
Secondary AntibodiesWhile not proteins used in conjunction with primary antibodies in the same context, secondary antibodies are crucial for detecting bound primary antibodies:
These antibodies and proteins are extensively used in research, diagnostics, and therapeutic applications, often in conjunction with TNF and PD-1 antibodies. The key findings from scientific literature on clone 1-2 citations focus on two main areas: (1) studies of cloning methods and efficiencies, and (2) the phenomenon of 'cloned journals' and issues around scientific citations. 1. Cloning Methods and Efficiencies:
2. Cloned Journals and Citations:
Additional Relevant Context:
In summary, scientific literature reveals both technical advances in cloning methodology (with efficient screening and high success rates) and serious issues in publication ethics caused by cloned journals and unreliable citation practices. Dosing regimens for clone 1-2 antibodies in mouse models can vary significantly depending on several experimental factors, though specific standardized protocols are not well-established in the literature for this particular isotype control. Key Factors Influencing Dosing VariationsThe dosing regimens for clone 1-2 are primarily influenced by the mouse strain being used, the specific disease model being studied, and the experimental objectives. As a rat IgG2b isotype control, clone 1-2 serves as a negative control antibody rather than having therapeutic targeting properties. Its dosing must be matched to the experimental antibody being tested to ensure proper control conditions. General Considerations for Isotype Control DosingSince clone 1-2 functions as an isotype control, its dosing should mirror that of the test antibody in the same experiment. This means that the amount, route of administration, and timing of clone 1-2 administration should match the experimental antibody to provide valid negative control data. The antibody is designed to have minimal cross-reactivity with mouse cells and tissues. Lack of Standardized ProtocolsUnlike therapeutic antibodies such as checkpoint inhibitors (which have well-defined dosing ranges like 200-500 μg per mouse for anti-PD-1 antibodies), clone 1-2 does not have established independent dosing guidelines. This is because it is not used to deplete specific cell types or neutralize cytokines but solely serves as a control. Researchers must determine appropriate dosing based on the specific requirements of their experimental system and the dosing of the primary antibody being investigated. The variability in dosing regimens ultimately reflects the diverse applications and experimental designs across different mouse models, making it essential for researchers to optimize dosing parameters for their specific experimental context. References & Citations1.) Hawman DW, et al. (2021) Microorganisms 9(2):279 Journal Link |
Related Products
Prod No. | Description |
|---|---|
B571 | |
B661 | |
B582 |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
